Hope grows here for cancer patients
“Rexanna’s Foundation names grant after Amarillo resident Bruce Campbell, as he navigates journey of battling disease by being a light to others.”

Surviving lung cancer with a flair for hope
“As a nonsmoker her entire life, Peg Berens never gave much thought to lung cancer. She was focused on her family and her career in interior design.”

2022 State of Lung Cancer Report: Critically Low Lung Cancer Screening Rates Reveal Opportunity to Save More Lives
“The 2022 State of Lung Cancer report by the American Lung Association revealed that only 5.8% of eligible Americans had been screened for lung cancer in 2021, and some states had screening rates as low as 1%. The 5th annual report highlighted how the toll of lung cancer varied by state and examined key indicators throughout the United States—including new cases, survival, early diagnosis, surgical treatment, lack of treatment, and screening rates.”

Frontline Nivolumab/Ipilimumab + Chemotherapy Benefit Extends to Histology and PD-L1 Subgroups in mNSCLC
“Updated data from the phase 3 CheckMate 9LA trial showed that the combination of nivolumab, ipilimumab, and 2 cycles of chemotherapy elicited survival benefit in patients with treatment-naïve metastatic non–small cell lung cancer.”

Biomarker Testing Provides ‘Real Potential’ to Manage Lung Cancer
“The use of biomarkers in lung cancer has grown by leaps and bounds from where it was 20 years ago.”

Sunvozertinib Shows Activity and Tolerability in EGFR Exon 20+ NSCLC
“Sunvozertinib (DZD9008) has demonstrated activity in patients with non–small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation across mutation types and prior treatments, according to data pooled from 3 phase 1/2 clinical trials. Findings from the clinical trials were presented at the International Association for the Study of Lung Cancer 2022 North America Conference on Lung Cancer.1

What doctors wish patients knew about lung cancer screening
“Lung cancer causes about 160,000 U.S. deaths a year, which is greater than the toll of the next three most common cancers—colon, breast and prostate—combined. Yet only about 30% of lung cancer cases are diagnosed early with most patients diagnosed at a far less treatable, later stage of the disease.”

Libtayo’s Approval Part of the ‘Renaissance’ of Lung Cancer Advancements
“In recent years, there has been a “renaissance of therapies,” for the treatment of lung cancer, especially with the addition of immunotherapy and targeted treatments, according to Dr. Edward Kim, who is the physician in chief at City of Hope, Orange County and vice physician in chief at the City of Hope National Medical Center.”

Lung Cancer Does Not Discriminate
“Up to a third of lung cancer patients that cardiothoracic surgeon Dr Anand Sachithanandan sees are non-smokers or have never smoked. Clinical oncologist Dr Tho Lye Mun says half of his patients are non or very light smokers; most of them are women.”


New approach to lung cancer has patient diagnosed and treated all in one day
“CHICAGO Ill. (WGN-TV) — A new approach to lung cancer: From diagnosis to treatment, all in one day. It’s typically a nerve-wracking delay. You’re told you have a suspicious spot but may have to wait months for a definitive diagnosis and treatment. A local team of doctors wants to make the process more immediate, diagnosing and operating on lung cancer patients the same day.”

A More Precise Approach to Small Cell Lung Cancer Treatment
“In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, a medical oncologist and hematologists at Cancer Treatment Centers of America Atlanta, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer (SCLC).”